Capricor Therapeutics (CAPR) EBT Margin (2011 - 2024)
Capricor Therapeutics (CAPR) posted quarterly EBT Margin of 56.9% for Q4 2024, down 5225.0% year-over-year from 1.11% in Q1 2024, and up 99.02% quarter-over-quarter from 5794.83% in Q3 2024.
Capricor Therapeutics (CAPR) EBT Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBT Margin history runs 13 years deep, the most recent figure standing at 56.9% for Q4 2024.
- In Q4 2024, EBT Margin fell 5225.0% year-over-year to 56.9%; the TTM figure through Sep 2025 stood at 1614.0% (down 92197.0% YoY), while the FY2024 annual figure was 181.7%, down 3697.0% from the prior year.
- EBT Margin for Q4 2024 stood at 56.9%, up from 5794.83% in the prior quarter.
- The five-year high for EBT Margin was 4.65% in Q4 2023, with the low at 71092.46% in Q3 2020.
- The 5-year median for EBT Margin is 1009.21% (2022), against an average of 7877.83%.
- The sharpest annual moves came in 2020 and 2021: EBT Margin slumped 6988160 bps in 2020, then surged 1879918 bps in 2021.
- Capricor Therapeutics' EBT Margin stood at 7229.02% in 2020, then surged by 66 bps to 2482.54% in 2021, then jumped by 66 bps to 849.84% in 2022, then surged by 99 bps to 4.65% in 2023, then tumbled by 1125 bps to 56.9% in 2024.
- Business Quant data shows CAPR's EBT Margin at 56.9% in Q4 2024, 5794.83% in Q3 2024, and 582.84% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -56.90% |
| Sep 30, 2024 | -5,794.83% |
| Jun 30, 2024 | -582.84% |
| Mar 31, 2024 | -412.24% |
| Dec 31, 2023 | -4.65% |
| Sep 30, 2023 | -171.74% |
| Jun 30, 2023 | -497.20% |
| Mar 31, 2023 | -275.46% |
| Dec 31, 2022 | -849.84% |
| Sep 30, 2022 | -1,523.03% |
| Jun 30, 2021 | -2,482.54% |
| Mar 31, 2021 | -12,622.31% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -71,092.46% |
| Jun 30, 2020 | -21,281.72% |
| Mar 31, 2020 | -1,168.58% |
| Dec 31, 2019 | -661.60% |
| Sep 30, 2019 | -1,210.86% |
| Jun 30, 2019 | -503.64% |
| Mar 31, 2019 | -1,308.05% |